Embr.Si
Embre SSI is a Singapore-based company operating in the Advanced Medical Equipment & Technology industry, specializing in the development and commercialization of medical devices and technologies.
Business. Embre SSI is a Singapore-based company operating in the Advanced Medical Equipment & Technology industry, specializing in the development and commercialization of medical devices and technologies.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Embre SSI is a Singapore-based company operating in the Advanced Medical Equipment & Technology industry, specializing in the development and commercialization of medical devices and technologies.
Embre's capital structure is characterized by a debt-to-equity ratio of 1.58, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.17, suggesting limited short-term liquidity cushion. Free cash flow is negative at -3.702 million SGD, and operating cash flow is also negative at -0.36 million SGD, indicating ongoing cash burn. The company holds 0.557 million SGD in cash and equivalents, which is insufficient to cover its long-term debt of 2.413 million SGD.
Profitability metrics are weak, with a return on equity of -2.5966 and a return on assets of -0.781, both significantly below industry norms for medical equipment firms. Operating income is negative at -3.914 million SGD, and net income is also negative at -3.965 million SGD, reflecting ongoing losses. Gross profit of 1.937 million SGD is insufficient to cover operating expenses, highlighting operational inefficiencies.
Embre does not disclose segment-level revenue data, and geographic exposure is not specified in the available financials. The company's revenue concentration is not quantified, but the absence of geographic diversification data suggests potential exposure to regional market risks.
Growth trajectory is negative, with no revenue growth data provided and a net loss in the latest period. The company has not disclosed capital expenditure plans, and the absence of positive cash flow from operations suggests limited capacity for organic growth.
Risk factors include liquidity constraints and a high debt burden relative to equity. The company's net cash position is negative after subtracting total debt, raising concerns about its ability to meet long-term obligations. Dilution risk is assessed as low, with no recent share issuance or dilution events reported. No adjustments to valuations have been applied, indicating no material changes in capital structure or valuation assumptions.
Recent events include the latest financial filing, which discloses ongoing losses and negative cash flow. No material events or regulatory actions are reported in the available data.
- EmBre is operating at a loss with negative operating and free cash flow, indicating financial distress.
- The company's debt-to-equity ratio is high, and liquidity is constrained, raising concerns about solvency.
- Profitability metrics are significantly below industry norms, suggesting operational inefficiencies.
- No segment or geographic diversification data is available, limiting visibility into revenue drivers.
- Growth prospects are unclear, with no capital expenditure and negative cash flow from operations.
- Dilution risk is low, but liquidity and solvency risks remain elevated.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- EMBR.SI Market data — financials · 2026-05-27